Hikma Pharmaceuticals/£HIK

07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX

About Hikma Pharmaceuticals

Hikma Pharmaceuticals is a multinational pharmaceutical company headquartered in London, United Kingdom. It specializes in the development, manufacturing, and marketing of a broad portfolio of branded and non-branded generic and in-licensed pharmaceutical products. The company operates across three main segments: Injectables, Generics, and Branded, serving hospitals, pharmacies, and wholesalers. Hikma was founded in 1978 in Amman, Jordan, and has since expanded its operations globally, maintaining a significant presence in the Middle East and North Africa, the United States, and Europe. Its strategic positioning is supported by its extensive manufacturing capabilities and a strong commitment to quality and regulatory compliance.

Ticker

£HIK

Primary listing

LSE

Industry

Pharmaceuticals

Employees

9,500

HIK Metrics

BasicAdvanced
£4.5B
16.95
£1.19
0.45
£0.60
2.98%

What the Analysts think about HIK

Analyst ratings (Buy, Hold, Sell) for Hikma Pharmaceuticals stock.

Bulls say / Bears say

Hikma Pharmaceuticals plans to invest $1 billion by 2030 to expand its U.S. manufacturing and R&D capabilities, enhancing its production capacity and potentially increasing market share. (prnewswire.com)
The company has acquired the FDA-approved ANDA for trametinib tablets, securing 180 days of U.S. generic market exclusivity, which could boost revenue in the oncology segment. (prnewswire.com)
Hikma reported a 19% increase in core operating profit for 2023, driven by strong performance in its generics business, indicating robust financial health. (reuters.com)
Hikma forecasts a slight decline in profit for 2024, projecting a core operating profit between $660 million and $700 million, compared to $707 million in 2023. (reuters.com)
The company's total liabilities increased by 13.8% in 2024, reaching $2.812 billion, which may raise concerns about its debt levels. (barchart.com)
Hikma's operating cash flow decreased by 23.47% in 2024, indicating potential challenges in cash generation. (barchart.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.

HIK Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

HIK Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy £HIK

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs